EP. 1: ASCENT-03 Results: Sacituzumab Govitecan in First-Line TNBC ByLaura Huppert, MDDecember 19th 2025
EP. 2: ASCENT-03 and ASCENT-04 Sacituzumab Govitecan Safety Data Shared at SABCS 2025 ByLaura Huppert, MDDecember 19th 2025
EP. 3: ASCENT-04: Outcomes With Sacituzumab Govitecan Plus Pembrolizumab In First-Line TNBCByLaura Huppert, MDJanuary 6th 2026
EP. 4: PROs From ASCENT-04 Study of Sacituzumab Govitecan Plus Pembrolizumab in First-Line TNBCByLaura Huppert, MDJanuary 6th 2026
